University of Birmingham scientists introduce a carrageenan-based nasal spray for COVID-19 eleven (11) months after I showed my readers how to make their own spray at-home (Fancy that!)

UK scientists finalising nasal spray that prevents Covid infection | Business Standard News (business-standard.com)

The spray is a combination of an antiviral agent called carrageenan, commonly used in foods as a thickening agent, and a solution called gellan a gelling agent selected for its ability to stick to cells inside the nose.

Antivirus nasal spray you can make at home (Git-R-Done) | For Seekers & Other Heretics (wordpress.com)

The photo is one of the many bottles of saline/iota carrageenan/polysorbate 20 (antivirus) nasal spray I processed on 3-17-2020 in my lab. Giveaways, yes, to family, friends & volunteers.

Here is my step-by-step guide to making up the spray at home:

Comment: I began seeing a large number of downloads of my nasal spray creation guidelines from people in the UK beginning shortly after March 22, 2020.

Familiar pattern perhaps?

Ependyma & CSF & stem cells & ALS: Connect the dots | For Seekers & Other Heretics (wordpress.com)

Getting stem cells to target using magnetic means | For Seekers & Other Heretics (wordpress.com)

There are many other similar “coincidences” down through the years but in the final analysis, what counts is folks get the help they need to combat acute & chronic diseases & conditions.

Copyright 2021 by Dr. Anthony G. Payne. All rights reserved.

Ependyma & CSF & stem cells & ALS: Connect the dots

Public Release: 21-Jul-2016

Cerebrospinal fluid signals control the behavior of stem cells in the brain

University of Basel

https://www.eurekalert.org/pub_releases/2016-07/uob-cfs072016.php

---

Med Hypotheses. 2009 May;72(5):548-50. doi: 10.1016/j.mehy.2008.12.032. Epub 2009 Feb 5.

Experimental regimen targeting the ependyma slows disease progression in four patients with amyotrophic lateral sclerosis.

Payne AG¹.

Author information

• ¹DrAGPayne@yahoo.com

Abstract

In this paper the author proposes that at least some forms of sporadic ALS (amyotrophic lateral sclerosis) arise due to the effects of neurotoxic compounds synthesized by defective ependymal cells in the brain. These cells produce cerebrospinal fluid (CSF) that is laden with neurotoxic compounds that bring about motor neuron die-off. Evidence is garnered from various animal studies to demonstrate the toxicity of CSF taken from ALS patients and by virtue of the proposed mechanism (defective ependymal cells). In addition, a regimen created by the author is introduced; a regimen that has been used by four (4) sporadic ALS patients since 2005 resulting in what appears to be a slowing of disease progression. All four patients have significantly outlived best estimates of their survival tendered by their neurologists.

PMID:

19200662

DOI:

10.1016/j.mehy.2008.12.032

Experimental regimen targeting the ependyma slows disease progression in four patitents with ALS

 

Citation: Payne AG. ,’Experimental regimen targeting the ependyma slows disease progression in four patitents with ALS,’ Med Hypotheses (2009), doi:10.1016/j.mehy.2008.12.032  Experimental regimen targeting the ependyma slows disease progression in four patients with amyotrophic lateral sclerosis Dr. Anthony G. Payne* E-mail: DrAGPayne@yahoo.com SUMMARY  In this paper the author proposes that at least some forms of sporadic ALS (amyotrophic lateral sclerosis) arise due to the effects of neurotoxic compounds synthesized by defective ependymal cells in the brain. These cells produce cerebrospinal fluid (CSF) that is laden with neurotoxic compounds that bring about motor neuron die-off. Evidence is garnered from various animal studies to demonstrate the toxicity of CSF taken from ALS patients and by virtue of the proposed mechanism (defective ependymal cells). In addition, a regimen created by the author is introduced; a regimen that has been used by four (4) sporadic ALS patients since 2005 resulting in what appears to be a slowing of disease progression. All four patients have significantly outlived best estimates of their survival tendered by their neurologists. 2009 Published by Elsevier Ltd.